The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Corbus Pharmaceuticals Holdings's share price is $33.50.
Corbus Pharmaceuticals Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, Corbus Pharmaceuticals Holdings's PS Ratio for today is .
The historical rank and industry rank for Corbus Pharmaceuticals Holdings's PS Ratio or its related term are showing as below:
During the past 11 years, Corbus Pharmaceuticals Holdings's highest PS Ratio was 1953.48. The lowest was 7.61. And the median was 111.94.
CRBP's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.98 * Ranked among companies with meaningful PS Ratio only.
During the past 11 years, Corbus Pharmaceuticals Holdings's highest 3-Year average Revenue per Share Growth Rate was 130.00% per year. The lowest was -56.10% per year. And the median was 30.60% per year.
Back to Basics: PS Ratio
Corbus Pharmaceuticals Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Corbus Pharmaceuticals Holdings's PS Ratio
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's PS Ratio falls into.
Corbus Pharmaceuticals Holdings PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Corbus Pharmaceuticals Holdings's Share Price of today is $33.50. Corbus Pharmaceuticals Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Corbus Pharmaceuticals Holdings (NAS:CRBP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Corbus Pharmaceuticals Holdings PS Ratio Related Terms
Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRBP has been successfully added to your 